Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT04621851 Recruiting - Clinical trials for Chronic Myeloid Leukemia

Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation

Start date: September 30, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to investigate the safety profile of TKI discontinuation in clinical practice, with particular regard on the risk of progression after treatment discontinuation.

NCT ID: NCT04616274 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia

Start date: July 1, 2020
Phase:
Study type: Observational

Venetoclax is a treatment for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, the pharmacokinetic data in Chinese population, as well as the change of venetoclax plasma concentration while taking CYP enzyme inducers or inhibitors, remained unknown so far. Therefore, the aim of this study is to investigate the pharmacokinetic characteristics of venetoclax.

NCT ID: NCT04613622 Recruiting - Clinical trials for Acute Myeloid Leukemia

Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia

Start date: August 1, 2020
Phase:
Study type: Observational

Venetoclax is a treatment for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, the pharmacokinetic data in Chinese population, as well as the change of venetoclax plasma concentration while taking CYP enzyme inducers or inhibitors, remained unknown so far. Therefore, the aim of this study is to investigate the pharmacokinetic characteristics of venetoclax.

NCT ID: NCT04610125 Recruiting - Lymphoma Clinical Trials

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Start date: June 23, 2020
Phase: N/A
Study type: Interventional

This is an open, single-arm, prospective,clinical study to evaluate efficacy and safety of Auto CAR-T cell injection in the treatment of recurrent or refractory Hematopoietic and Lymphoid Tissue Tumors in Children

NCT ID: NCT04606433 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Start date: November 4, 2020
Phase: Phase 1
Study type: Interventional

An open, multicenter, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics, and antitumor activity of GNC-038 quad-specific antibody injection in relapsed or refractory non-Hodgkin's lymphoma, relapsed or refractory acute lymphoblastic leukemia, and refractory or metastatic solid tumors.

NCT ID: NCT04605666 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia, in Relapse

CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia

Start date: May 1, 2020
Phase: Phase 2
Study type: Interventional

Relapsed and refractory B cell acute lymphoblastic leukemia (B-ALL) shows unfavorable prognosis, especially for adult patients. Besides, minimal residual disease (MRD) positive at transplant has been considered risk factor for relapse after transplantation. Worse yet, there is no standard management for these patients. Chimeric antigen receptor T cells (CAR-T cells) has been recognized a promising treatment option for treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and safety of chimeric antigen receptor 19 (CD19-CAR-T2 Cells) infusions in patients with CD19+ ALL.

NCT ID: NCT04603872 Recruiting - Clinical trials for Multiple Myeloma in Relapse

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Start date: November 1, 2020
Phase: Early Phase 1
Study type: Interventional

A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

NCT ID: NCT04601584 Recruiting - ALL Clinical Trials

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

Start date: October 15, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

It is an open-label dose-escalating study in sequential cohorts to assess safety and pharmacokinetics of GNR-084.

NCT ID: NCT04593277 Recruiting - Lymphoma Clinical Trials

Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study

Start date: October 23, 2022
Phase: N/A
Study type: Interventional

This trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors. By improving access to survivorship resources, health literacy, self-management skills, and support, an interactive survivorship program may help to improve adherence to adolescent and young adult healthcare guidelines and reduce cancer-related distress.

NCT ID: NCT04589728 Recruiting - Clinical trials for Acute Myeloid Leukemia

Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Start date: February 23, 2021
Phase:
Study type: Observational

This is an retrospective and prospective observational multinstitutional study to evaluate the impact on outcome of the combination of HMA plus venetoclax in AML patients unfit for intensive chemotherapy in a "real-life" scenario. No additional procedures or visits other than those required by normal clinical practice will be required. Patients will be observed for at least 24 months.